Clinical trials: Breast Adenocarcinoma
Breast Cancer
Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ or Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation during surgery followed by external-beam radiation to the entire breast may kill more tumor cells.
- Trial name
- NCT00054301
- Testing
- adjuvant therapy, conventional surgery, intraoperative radiation therapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Case Comprehensive Cancer Center
Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
This randomized phase III clinical trial studies how well tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy work in treating patients with breast cancer that has spread from where it began in…
- Conditions
- Breast Ductal Carcinoma In Situ, Invasive Breast Carcinoma, Multicentric Breast Carcinoma, Multifocal Breast Carcinoma
- Trial name
- NCT01272037
- Testing
- Anastrozole, Exemestane, Laboratory Biomarker Analysis
- Where
- 1,568 sites in United States, Canada and 8 more
- Volunteers
- 5,018 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer
This phase 1b trial studies the biologic effect of 9cUAB30 on early stage breast cancer. 9cUAB30 is a retinoid X receptor (RXR)-selective retinoid that acts in a tissue selective manner with the goal of minimizing side effects, a…
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT02876640
- Testing
- Biospecimen Collection, Retinoid 9cUAB30, Therapeutic Conventional Surgery
- Where
- 5 sites in United States
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Vaccine Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and kill more tumor cells.
- Trial name
- NCT00304096
- Testing
- synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Virginia
Ductal Breast Carcinoma in Situ, Invasive Breast Cancer
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
An explanatory study comparing complementary treatment to breast conservative surgery with radiation therapy DCIS, T1-T2 N0 M0 (AJCC v8) 1 week schedule vs 3.1 weeks standard schedule, in order to determine the equivalence of…
- Conditions
- Ductal Breast Carcinoma in Situ, Invasive Breast Cancer, Early-stage Breast Cancer, Stage 0 Breast Cancer
- Trial name
- NCT05318274
- Testing
- Hypofractionated radiotherapy
- Where
- Mexico
- Volunteers
- 72 people
- Sponsor
- Coordinación de Investigación en Salud, Mexico
Advanced Solid Tumors, Lymphoma
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance.
- Conditions
- Advanced Solid Tumors, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT03841110
- Testing
- FT500, Nivolumab, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Fate Therapeutics
Solid Tumor, Lymphoma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
This is a single arm Phase 2 study of the combination of adenoviral p53 (Ad-p53) gene therapy administered intra-tumorally with approved immune checkpoint inhibitors in patients with recurrent or metastatic cancers.
- Trial name
- NCT03544723
- Testing
- Ad-p53
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- MultiVir, Inc.
Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
This pilot trial studies how well a diabetes prevention program with or without hunger training works in helping to lower breast cancer risk in obese participants.
- Conditions
- Deleterious BRCA1 Gene Mutation, Deleterious BRCA2 Gene Mutation, Ductal Breast Carcinoma In Situ, Obesity
- Trial name
- NCT03546972
- Testing
- Behavioral, Psychological or Informational Intervention, Questionnaire Administration
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm
Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up
The aim of the study is to evaluate whether tamoxifen at a low dose of 5mg/d reduces in the long term the incidence of invasive breast cancer and ductal carcinoma in situ, DCIS (DIN 1c, 2, 3) of the breast, in woman operated for…
- Conditions
- Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm, Breast Neoplasms, Atypical Hyperplasia
- Trial name
- TAM-01 (NCT01357772)
- Testing
- Tamoxifen
- Where
- 14 sites in Italy
- Volunteers
- 500 people
- Sponsor
- Andrea DeCensi
Breast Neoplasms, Breast Diseases
Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)
Standard breast MRI studies often have lengthy protocols that make them inherently expensive and time-consuming. Several studies of the use of abbreviated MRI protocols have shown that the shorter protocols have diagnostic…
- Conditions
- Breast Neoplasms, Breast Diseases, Breast Fibroadenoma, Breast Cancer
- Trial name
- NCT04341129
- Testing
- Abbreviated MRI protocol: initial experience with Dotarem® (Gadoterate Meglumine)
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Chicago
DCIS
Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCIS
In the case of a patient undergoing total mastectomy for intraductal carcinoma (DCIS), the sentinel lymph node is not excised during the primary surgery but only marked for identification.
- Trial name
- NCT05912569
- Testing
- Delay sentinel node biopsy
- Where
- South Korea
- Volunteers
- 84 people
- Sponsor
- Seoul National University Hospital
Ductal Breast Carcinoma In Situ, Postmenopausal
The PROMISE Study: Duavee in Women With DCIS
The main purpose of this study is to determine if taking the study drug, conjugated estrogens/bazedoxifene (Duavee®) causes any changes in the proliferation markers within the breast tissue of the study subjects.
- Trial name
- NCT02694809
- Testing
- Conjugated Estrogens/Bazedoxifene, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 10 sites in United States
- Volunteers
- 142 people
- Sponsor
- Northwestern University
Carcinomas, Amyloidosis
B-Receptor Signaling in Cardiomyopathy
We hope to determine the importance of different genes (including B receptors) in anthracycline-induced cardiomyopathy. This has important benefits to patients exposed to anthracyclines, as this could help determine whether…
- Conditions
- Carcinomas, Amyloidosis, Anal Cancer, Anemia
- Trial name
- NCT01135849
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- Daniel Bernstein
Breast Cancer
A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS
The purpose of the study is to treat patients with Ductal carcinoma in situ (DCIS) with a combined treatment of DC1 vaccine with Trastuzumab.
- Trial name
- NCT02336984
- Testing
- HER-2 pulsed DC1, trastuzumab, pertuzumab
- Where
- 2 sites in United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer
Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00009763
- Testing
- filgrastim, monoclonal antibody m170, cyclosporine
- Where
- United States
- Sponsor
- University of California, Davis
Outcome of Breast Cancer
Study of the Influence of Ductal Carcinoma in Situ on the Outcome of Invasive Breast Cancer
A prospective observational longitudinal study of 464 patients was performed between 2010 and 2015. Patients with invasive ductal carcinoma (IDC) and ductal carcinoma in situ associated to invasive ductal carcinoma (DCIS +IDC)…
- Trial name
- NCT03669952
- Testing
- None intervention
- Volunteers
- 464 people
- Sponsor
- Omphis Foundation
Breast Cancer, Ovarian Cancer
Vaccine Therapy Plus Interleukin-2 in Treating Women With Stage IV, Recurrent, or Progressive Breast or Ovarian Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Interleukin-2 may stimulate a person's white blood cells to kill tumor cells.
- Trial name
- NCT00019916
- Testing
- aldesleukin, p53 peptide vaccine, in vitro-treated peripheral blood stem cell transplantation
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer
CI-1040 in Treating Patients With Advanced Breast, Colon, Pancreatic, or Non-Small Cell Lung Cancer
RATIONALE: CI-1040 may stop the growth of tumors by blocking the enzymes necessary for cancer cell growth and by stopping blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Lung Cancer, Pancreatic Cancer
- Trial name
- NCT00033384
- Testing
- CI-1040
- Where
- United States
- Sponsor
- University of Alabama at Birmingham
Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating
Abbreviated Breast MRI After Cancer Treatment
500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1.
- Trial name
- NCT03664778
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- University of Pennsylvania
Breast Cancer, Invasive Breast Cancer
BrUOG 351: PRE-OPERATIVE APBI USING NIBB
Partial breast irradiation is typically performed after surgical removal of the tumor. Partial breast irradiation allows for focused radiation to the area from which the cancer was removed, sparing breast tissue from the…
- Conditions
- Breast Cancer, Invasive Breast Cancer, Ductal Carcinoma in Situ
- Trial name
- 351 (NCT03437915)
- Testing
- NIBB: accuboost, Partial mastectomy
- Sponsor
- Jaroslaw Hepel